These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9371009)

  • 1. Drug-induced disorders.
    Holland EG; Degruy FV
    Am Fam Physician; 1997 Nov; 56(7):1781-8, 1791-2. PubMed ID: 9371009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS).
    Benjamin DM; Pendrak RF
    J Clin Pharmacol; 2003 Jul; 43(7):754-9. PubMed ID: 12856390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug misadventuring in neonatal nephrology.
    Fanos V; Cataldi L
    Pediatr Med Chir; 2002; 24(2):150-6. PubMed ID: 11987523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-related morbidity and mortality. A cost-of-illness model.
    Johnson JA; Bootman JL
    Arch Intern Med; 1995 Oct; 155(18):1949-56. PubMed ID: 7575048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.
    Moore TJ; Cohen MR; Furberg CD
    Arch Intern Med; 2007 Sep; 167(16):1752-9. PubMed ID: 17846394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions.
    O'Donnell J
    Leg Med; 1994; ():229-67. PubMed ID: 7830481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals.
    Takata GS; Mason W; Taketomo C; Logsdon T; Sharek PJ
    Pediatrics; 2008 Apr; 121(4):e927-35. PubMed ID: 18381521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adverse drug events in out-patients as the cause of an initial consultation to neurology].
    Ortin Castaño A; Otero MJ
    Neurologia; 2006 Jun; 21(5):232-8. PubMed ID: 16788865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project--six sites, United States, January 1-June 15, 2004.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Apr; 54(15):380-3. PubMed ID: 15843786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-related deaths in a university central hospital.
    Juntti-Patinen L; Neuvonen PJ
    Eur J Clin Pharmacol; 2002 Oct; 58(7):479-82. PubMed ID: 12389071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the quality of adverse drug reaction reporting by 4th-year medical students.
    Rosebraugh CJ; Tsong Y; Zhou F; Chen M; Mackey AC; Flowers C; Toyer D; Flockhart DA; Honig PK
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):97-101. PubMed ID: 12642973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward improved adverse event/suspected adverse drug reaction reporting.
    Gross R; Strom BL
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
    [No Abstract]   [Full Text] [Related]  

  • 18. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis.
    Manley HJ; Cannella CA; Bailie GR; St Peter WL
    Am J Kidney Dis; 2005 Oct; 46(4):669-80. PubMed ID: 16183422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R; Wyeth J; Chen M; Cope JU
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.